What Is a Myotoxin? The Toxin That Destroys Muscle

A myotoxin is any toxin that directly damages skeletal muscle cells, and the term covers a surprisingly diverse family of molecules found mostly in snake venoms but also in certain mushrooms and other organisms. These toxins punch holes in muscle cell membranes, flood the cells with calcium, and trigger a cascade of destruction that can range from localized tissue death at a bite site to full-blown systemic muscle breakdown threatening the kidneys and heart. The biology behind myotoxins turns out to be more varied and more clinically consequential than the simple label suggests.

The Four Main Families of Myotoxins

Researchers group snake venom myotoxins into four broad categories based on their biochemistry and how they attack muscle: myotoxic phospholipases A2, small basic polypeptide toxins, cardiotoxins, and hemorrhagic myotoxins.¹ These categories matter because the mechanism of destruction differs meaningfully between them, which in turn shapes what treatments work and what complications develop. Phospholipases A2 are the most studied and the most common in viper venoms. Cardiotoxins show up primarily in cobra-family venoms. The small basic polypeptides, like crotamine from South American rattlesnakes, work through an entirely different pathway involving ion channels on muscle cells. Hemorrhagic myotoxins are metalloproteinases that damage blood vessels and muscle simultaneously, leading to the tissue destruction and swelling typical of severe viper bites.

How PLA2 Myotoxins Tear Apart Muscle Cells

The phospholipase A2 (PLA2) myotoxins are the workhorses of venom-induced muscle damage. They latch onto the outer membrane of a muscle cell, bind to specific sites on the surface, and then compromise the membrane’s integrity. Once the membrane is breached, calcium floods in. That calcium influx is the starting gun for a chain of destructive events inside the cell: the muscle fibers lock into an extreme contraction, internal enzymes called calpains activate and start digesting structural proteins, and the cell’s mitochondria become overloaded with calcium, effectively shutting down the cell’s energy supply.² The cell dies not from a single insult but from a pileup of simultaneous failures.

What makes this family of toxins particularly interesting is that not all PLA2 myotoxins actually function as enzymes. The “classic” versions, called Asp49 PLA2s, actively chew up phospholipids in the cell membrane, breaking down the molecular building blocks that hold the membrane together. Researchers confirmed that these enzymatic versions rapidly break apart specific phospholipids on the outer face of the muscle cell membrane but leave inner-layer phospholipids untouched.³ That selective destruction of the outer membrane layer is enough to fatally compromise the cell.

The Paradox of Non-Enzymatic Myotoxins

A whole subgroup of PLA2-like proteins have evolved a curious trick: they look like phospholipases but have lost the ability to actually break down phospholipids. In these variants, known as Lys49 myotoxins, a single amino acid substitution in their active site renders the enzymatic machinery inert. Yet they still destroy muscle cells with ruthless efficiency.⁴ These proteins punch holes in the plasma membrane through direct physical disruption rather than chemical digestion of phospholipids.⁵

This distinction has real clinical consequences. Treatments designed to block the enzymatic activity of PLA2s should, in theory, do nothing against Lys49 myotoxins. Research on Central American snake venoms showed exactly this pattern: the myotoxic effects of some venoms were effectively blocked by varespladib, a PLA2 inhibitor, confirming that their muscle damage was enzyme-driven, while the myotoxicity of other venoms from related species was not neutralized at all, revealing that non-PLA2 toxin types were responsible.⁶ A treatment that works brilliantly for one species’ bite may fail completely for a closely related snake. This is one reason snakebite medicine remains so challenging.

Crotamine and the Ion Channel Route

Not all myotoxins work by shredding membranes. Crotamine, a small protein found in the venom of South American rattlesnakes, attacks muscle through its sodium channels. Rather than punching holes in the cell surface, crotamine forces sodium channels open, causing uncontrolled muscle contraction and spastic paralysis, particularly in the hind limbs of experimental animals.⁷ At the tissue level, even very low concentrations of crotamine substantially increase the force of muscle contraction, which sounds like it could be useful until you realize that a muscle forced to contract far beyond its normal range tears itself apart.⁸

The crotamine pathway is a reminder that “myotoxin” is a functional label, not a structural one. These toxins share a target, skeletal muscle, but their mechanisms can be completely unrelated. A membrane disruptor and a sodium channel opener have nothing in common biochemically except the tissue they destroy.

When Muscle Death Goes Systemic

Localized muscle damage at a bite site is painful and can be disabling, but the real danger often comes when myotoxins cause widespread muscle breakdown throughout the body, a condition called rhabdomyolysis. When large amounts of muscle tissue die, the contents of those cells spill into the bloodstream. Among the most dangerous of those contents is myoglobin, the oxygen-carrying protein in muscle. Myoglobin is harmless inside a healthy muscle cell, but free myoglobin in the blood is filtered through the kidneys and can clog and damage the kidney’s tubules.

Animal studies using venom from the Australian king brown snake demonstrated this process in detail: myoglobin appeared in the urine, and microscopy showed myoglobin casts blocking kidney tubules at multiple points, leading to what researchers call “myoglobin cast nephropathy,” essentially kidney damage caused by having to filter too much muscle debris.⁹ The kidney damage progressed from cast formation within the first hour to outright tubular necrosis, the death of kidney tissue, by twelve hours.¹⁰ Acute kidney injury is one of the leading causes of death in severe snakebite envenoming.

Russell’s viper bites generally produce coagulopathy, neurotoxicity, and kidney damage, but severe muscle breakdown has been considered rare. A case report from Sri Lanka documented what appears to be the first instance of gross myoglobinuria, visible discoloration of the urine from myoglobin, in a child bitten by a Russell’s viper, with biochemical evidence of myotoxicity far exceeding previously reported levels for that species.¹¹ Cases like this suggest that myotoxicity from some species may be underrecognized, showing up only when clinicians specifically look for it.

The Potassium Problem

Kidney failure gets the most attention, but dying muscle cells release more than just myoglobin. About 70% of the body’s potassium lives inside muscle cells, so massive muscle breakdown dumps a dangerous load of potassium into the bloodstream.¹² High potassium levels, hyperkalemia, can cause life-threatening heart arrhythmias. This is the same mechanism behind cardiac arrest sometimes seen when certain anesthetic drugs trigger rhabdomyolysis in susceptible patients.¹³ In a snakebite victim with significant myotoxicity, monitoring heart rhythm and blood potassium is as urgent as managing the local wound.

Mushrooms That Destroy Muscle

Myotoxins are not exclusive to snake venom. Certain mushrooms produce compounds that trigger rhabdomyolysis in people who eat them. Mushroom poisoning has been formally classified to include a “myotoxic” category, covering both rapid-onset rhabdomyolysis from Russula species and delayed-onset muscle breakdown from Tricholoma species.¹⁴

Tricholoma equestre, known as the man on horseback or yellow knight mushroom, was long considered a choice edible species in parts of Europe. Then reports began emerging of people developing severe rhabdomyolysis after eating it repeatedly. A Lithuanian case series documented four poisoning cases between 2004 and 2013, including one death. Symptoms included fatigue, muscle pain, profuse sweating, and eventually respiratory failure. Blood tests confirmed severe muscle damage with highly elevated enzyme levels.¹⁵ The exact myotoxic compound in these mushrooms has not been fully characterized, making them harder to study than snake venom myotoxins, where the individual proteins can be isolated and tested.

Detecting Myotoxicity Early

Clinicians typically diagnose muscle damage by measuring creatine kinase (CK) in the blood, an enzyme that leaks out of damaged muscle cells. But CK levels can take hours to rise significantly after a snakebite, creating a window where a patient may be developing severe myotoxicity that blood tests haven’t caught yet. Researchers have been investigating a more specific form of the enzyme, CK-MM, which comes exclusively from skeletal muscle. In an animal study of Australian myotoxic snake envenoming, CK-MM activity was a substantially better predictor of muscle damage than standard CK in the first hours after venom exposure.¹⁶ If validated in human patients, this kind of biomarker could help clinicians intervene before the systemic cascade of rhabdomyolysis, kidney injury, and electrolyte imbalance gains momentum.

Why Antivenom Often Cannot Prevent Muscle Damage

Antivenom is the standard treatment for snakebite, and it works well against many systemic effects, particularly blood clotting problems. But myotoxicity is a different story. Venom-induced muscle damage begins within minutes of a bite, long before most patients reach a hospital and receive antivenom. Research examining wound fluid after envenomation found that when antivenom was given after the venom had already been injected, rather than mixed with venom beforehand, its ability to reduce local tissue damage dropped sharply. The very rapid onset of venom-induced destruction at the bite site makes local pathology difficult to neutralize once it has started.¹⁷

This is one of the central frustrations of snakebite medicine. Antivenom given intravenously at a hospital can mop up venom circulating in the bloodstream and prevent further systemic spread, but it typically arrives too late to save the muscle tissue at the bite site. The damage is already done by the time the IV drip starts.

Varespladib and the Search for a Field Antidote

The limitations of antivenom have driven interest in small-molecule drugs that could be carried in a first-aid kit and used immediately after a bite, before hospital care is available. Varespladib (also known as LY315920), a synthetic PLA2 inhibitor originally developed for other purposes, has emerged as one of the most promising candidates. When injected directly at the site of venom exposure in animal experiments, varespladib produced large reductions in muscle damage caused by several PLA2-containing venoms, suggesting it could serve as a field antidote to limit myonecrosis.¹⁸

Separate experiments showed that varespladib could completely abolish both the muscle-paralyzing and muscle-damaging activity of crotoxin, the main toxic component of South American rattlesnake venom, when mixed with the toxin before exposure.¹⁹ The drug is still being tested in clinical trials for human snakebite, but the concept is tantalizing: a single pill or injection given in the field, minutes after a bite, that blocks the enzymatic destruction before it cascades out of control. The catch, as noted earlier, is that varespladib only works against PLA2-mediated myotoxicity. Venoms that rely on non-enzymatic myotoxins or metalloproteinases would need a different approach.

Long-Term Disability After Myotoxic Envenoming

Even when patients survive the acute crisis, the muscle damage from a myotoxic snakebite can leave lasting consequences. A population-based study in Sri Lanka found that roughly 3% of snakebite victims had musculoskeletal disabilities in their bitten limb that persisted for an average of over 13 years. The most common complaints were chronic pain, reduced muscle power, and limited range of motion. Nearly half of affected victims showed visible muscle wasting. Severe outcomes included fixed deformities and amputation.²⁰

Research into the mechanisms behind permanent muscle loss has pointed to metalloproteinase myotoxins, which damage not just the muscle fibers themselves but also the blood vessels and structural scaffolding that muscle needs to regenerate. Permanent muscle damage and the resulting disability frequently lead to amputation, trapping victims in poverty.²¹ This is a dimension of snakebite that public health discussions often miss: the people who survive are not necessarily “cured.” Myotoxic venom can end a limb’s usefulness permanently.

Compartment Syndrome and the Fasciotomy Debate

When severe swelling from a myotoxic bite causes pressure to build inside a closed muscle compartment, the blood supply to the tissue can be cut off. This is compartment syndrome, and in many surgical contexts the standard treatment is fasciotomy, cutting open the tissue encasing the compartment to relieve pressure. But snakebite-induced compartment syndrome has sparked a persistent debate in emergency medicine.

A scoping review of global literature found that patients treated with fasciotomy actually reported worse outcomes than those managed without surgery, including the only recorded amputations and deaths. Patients treated non-surgically were more likely to have serial pressure measurements guiding their care. Current WHO guidelines and North American expert consensus statements recommend initial non-surgical treatment with antivenom and serial pressure monitoring, advising against prophylactic fasciotomies and recommending surgery only when antivenom fails.²² A U.S.-focused review reached a similar conclusion, noting that compartment syndrome following North American snake envenomation is rare and supporting liberal antivenom use before resorting to the knife.²³

That said, some patients do develop dangerously high compartment pressures. A Korean case series documented patients with pressures reaching nearly 90 mmHg, well beyond the threshold where tissue starts dying, and fasciotomy was performed.²⁴ The message is not that fasciotomy is never warranted, but that it should be a last resort after antivenom has been tried. Cutting into a limb that has been envenomed by a coagulopathic or myotoxic snake carries its own substantial risks of bleeding and infection.

Why Some Prey Animals Resist Myotoxins

Not every animal is equally vulnerable. Ground squirrels that share habitat with rattlesnakes have evolved serum-based resistance to venom, with blood proteins that bind to and neutralize venom components. This resistance is population-specific and species-specific: squirrels from areas with local rattlesnake populations show higher binding affinity for the venom proteins of those local snakes compared to squirrels from areas without the same predators.²⁵ This kind of co-evolutionary arms race is part of why venom composition varies so much between snake populations. A myotoxin that works perfectly against one prey community may be neutralized by the blood chemistry of another, driving the evolution of new toxin variants. The myotoxins in a given snake’s venom are, in a sense, adapted to the specific muscle cells of its most common prey.²⁶ Humans, who are not the intended target, get caught in the crossfire of an evolutionary contest between snakes and rodents.